OncoMatch/Clinical Trials/NCT07660627
Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Official title: Determination of Minimal Residual Disease by Deep ctDNA Sequencing.
Is NCT07660627 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for esophageal adenocarcinoma.
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse/progression of disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Gastric Cancer
Pancreatic Cancer
Disease stage
Required: Stage 0, I, II
stage 0-2; locally advanced, potentially operable disease; metastatic disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07660627 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage 0 or I or II is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages